Related Experiment Video
Updated: Jul 8, 2026
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Evidence for intensive LDL-C lowering for acute coronary syndrome: Recommendations from the Lipid Association of
Raman Puri1, Vimal Mehta2, P Barton Duell3
1Indraprastha Apollo Hospitals, New Delhi, India.
Insights
Patients with acute coronary syndrome (ACS) face high cardiovascular risks. Early, aggressive treatment of high LDL cholesterol (LDL-C) with statins and other therapies can significantly reduce these risks and improve outcomes.
Area of Science:
- Cardiology
- Lipidology
- Preventive Medicine
Background:
- Patients with acute coronary syndrome (ACS) have a high risk of adverse cardiovascular events, especially within 30 days post-discharge.
- Persistent hypercholesterolemia after ACS discharge represents a missed opportunity for secondary prevention.
- South Asian populations exhibit earlier and more aggressive atherosclerotic cardiovascular disease, necessitating tailored interventions.
Purpose of the Study:
- To outline recommendations for earlier and more aggressive lipid-lowering treatment in ACS patients.
- To emphasize individualized LDL-C goals for high-risk individuals, particularly those of South Asian descent.
- To highlight the potential of timely and intensive hypercholesterolemia management in reducing morbidity and mortality.
Main Methods:
- Development of recommendations by the Lipid Association of India.
- Emphasis on early initiation of high-intensity statin therapy.
- Integration of goal-directed adjunctive treatments like ezetimibe and PCSK9 inhibitors.
Main Results:
- Individualized, aggressive low-density lipoprotein cholesterol (LDL-C) goals are recommended post-ACS.
- Rapid achievement of LDL-C targets is feasible with high-intensity statins and add-on therapies.
- Prompt lipid management can mitigate significant cardiovascular risks.
Conclusions:
- Aggressive LDL-C lowering within weeks of ACS is crucial for improving patient outcomes.
- Tailored lipid management strategies, especially for South Asian patients, can reduce cardiovascular morbidity and mortality.
- Optimized hypercholesterolemia treatment is a key component of secondary prevention in ACS.
Abstract:
Patients with acute coronary syndrome (ACS) have a high risk of subsequent adverse cardiovascular outcomes, particularly within the first 30 days. Although it is well documented that initiation of statin therapy in the setting of ACS improves short- and long-term cardiovascular outcomes, and achievement of lower levels of low density lipoprotein cholesterol (LDL-C) incrementally improves outcomes, many patients with ACS have persistent hypercholesterolemia after discharge from the hospital. This is a missed opportunity that prompted the Lipid Association of India to develop recommendations for earlier initiation of more aggressive LDL-C lowering treatment, particularly for patients of South Asian descent who are well-documented to have earlier onset of more aggressive atherosclerotic cardiovascular disease. The Lipid Association of India recommends individualized aggressive LDL-C goals after ACS, which can be rapidly achieved with high intensity statin therapy and subsequent goal-directed adjunctive treatment with ezetimibe and PCSK9 inhibitors. Improved treatment of hypercholesterolemia achieved within weeks after ACS has the potential to reduce the high rate of morbidity and mortality in these high risk patients.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Coronary Artery Disease IV: Preventive Measures
01:27Coronary Artery Disease V: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Angina IV: Management
01:26Atherosclerosis III: Management